No improvement in injection frequency or in visual outcome over time in two cohorts of patients from the same Swedish county treated for wet age-related macular degeneration
Marion Schroeder,1 Lena Rung,2 Monica Lövestam-Adrian1 1Division of Ophthalmology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, 2Department of Ophthalmology, Helsingborg Hospital, Helsingborg, Sweden Background: Although ranibizumab has...
Guardado en:
Autores principales: | Schroeder M, Rung L, Lövestam-Adrian M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fea7eba8d90a4f9680dda563a3d8c9d3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2017) -
Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes
por: Razi F, et al.
Publicado: (2016) -
Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
por: Pongsachareonnont P, et al.
Publicado: (2018) -
Quality of Life in Patients with Unresolved Facial Nerve Palsy and Exposure Keratopathy Treated by Upper Eyelid Gold Weight Loading
por: Nowak-Gospodarowicz I, et al.
Publicado: (2020) -
Ranibizumab in neovascular age-related macular degeneration: a 5-year follow-up
por: Cvetkova NP, et al.
Publicado: (2016)